Home › Companies › Celldex Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Celldex Therapeutics, Inc.’s Form 8-K, filed 2026-06-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Celldex Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Celldex Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Harry H. Penner, Jr. (Chair of the Board) | 59,455,265 | 1,047,261 | 181,190 | -- | 4,402,319 | Majority: yes |
| Elect Director: Anthony S. Marucci (Chief Executive Officer) | 60,218,830 | 282,968 | 181,918 | -- | 4,402,319 | Majority: yes |
| Elect Director: Keith L. Brownlie | 59,858,683 | 644,110 | 180,923 | -- | 4,402,319 | Majority: yes |
| Elect Director: Cheryl L. Cohen | 60,046,578 | 456,194 | 180,944 | -- | 4,402,319 | Majority: yes |
| Elect Director: Herbert J. Conrad | 59,524,978 | 975,608 | 183,130 | -- | 4,402,319 | Majority: yes |
| Elect Director: Rita I. Jain, M.D. | 59,495,870 | 1,000,240 | 187,606 | -- | 4,402,319 | Majority: yes |
| Elect Director: James J. Marino | 59,910,902 | 591,402 | 181,412 | -- | 4,402,319 | Majority: yes |
| Elect Director: Garry A. Neil, M.D. | 59,570,030 | 932,772 | 180,914 | -- | 4,402,319 | Majority: yes |
| Elect Director: Denice Torres | 60,135,775 | 366,304 | 181,637 | -- | 4,402,319 | Majority: yes |
| Proposal 2: The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | 64,712,039 | 174,706 | 199,290 | -- | -- | Majority: yes |
| Proposal 3: The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares. | 58,844,414 | 1,654,297 | 185,005 | -- | 4,402,319 | Majority: yes |
| Proposal 4: The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement. | 59,258,619 | 945,414 | 479,683 | -- | 4,402,319 | Majority: yes |
Source: Celldex Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-26 — read the filing on EDGAR.
Each item below shows how the 256 asset managers that disclosed a Celldex Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Celldex Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Proposal 4: The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement.”): 59,258,619 for, 945,414 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 75% for, 1% against (77% of the company cast a for/against vote).
The 254 asset managers below cast 99.4% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,278,271 | 3 | 1 | 0 | For |
| Wellington | 8,548,588 | 0 | 0 | 0 | For |
| Fidelity | 8,183,781 | 0 | 0 | 0 | For |
| Kynam Capital Management, LP | 0 | 0 | 5,732,474 | 0 | Abstain |
| BlackRock | 5,447,042 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,774,195 | 0 | 0 | 0 | For |
| State Street | 2,825,757 | 2,557 | 0 | 0 | For |
| Commodore Capital LP | 2,105,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,925,741 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 1,556,298 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1,466,071 | 0 | 0 | 0 | For |
| American Century | 1,431,695 | 0 | 0 | 0 | For |
| Charles Schwab | 1,260,972 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,030,888 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 1,025,000 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 879,713 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 831,196 | 0 | 0 | 0 | For |
| MONTANOVA CAPITAL, LLC | 801,097 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 754,119 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 716,270 | 0 | 0 | 0 | For |
| Northern Trust | 596,608 | 0 | 0 | 0 | For |
| Nuveen | 565,045 | 0 | 0 | 0 | For |
| Woodline Partners LP | 561,629 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
Showing the 25 largest of 254 asset managers. See all 254 in the interactive database.
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Proposal 3: The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 3,400,000 shares to 12,900,000 shares.”): 58,844,414 for, 1,654,297 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 75% for, 2% against (77% of the company cast a for/against vote).
The 67 asset managers below cast 97% of the shares they voted on this item FOR (27,218,113 for, 700,985 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,917 | 7,369 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 1,556,298 | 0 | 0 | 0 | For |
| State Street | 1,315,992 | 1,711 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 0 | 683,198 | 0 | 0 | Against |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 55,501 | 8,349 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Anthony S. Marucci (Chief Executive Officer)”): 60,218,830 for, 282,968 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 77% for, 0.4% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,350,185 for, 9,398 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,918 | 7,367 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,030 | 1,673 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Cheryl L. Cohen”): 60,046,578 for, 456,194 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 77% for, 0.6% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,350,185 for, 9,399 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,918 | 7,368 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,030 | 1,673 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Denice Torres”): 60,135,775 for, 366,304 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 77% for, 0.5% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,359,582 for, 1 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,679,284 | 1 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,317,703 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Garry A. Neil, M.D.”): 59,570,030 for, 932,772 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 1% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,343,911 for, 15,672 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,916 | 7,369 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,030 | 1,673 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Harry H. Penner, Jr. (Chair of the Board)”): 59,455,265 for, 1,047,261 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 1% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,340,221 for, 19,362 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,668,238 | 11,046 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,018 | 1,685 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Herbert J. Conrad”): 59,524,978 for, 975,608 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 1% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,343,872 for, 15,710 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,916 | 7,369 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,315,992 | 1,711 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: James J. Marino”): 59,910,902 for, 591,402 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 0.8% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,350,184 for, 9,399 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,671,917 | 7,368 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,030 | 1,673 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Keith L. Brownlie”): 59,858,683 for, 644,110 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 0.9% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,346,507 for, 13,076 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,668,239 | 11,045 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,316,030 | 1,673 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Elect Director: Rita I. Jain, M.D.”): 59,495,870 for, 1,000,240 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 76% for, 1% against (77% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,353,308 for, 6,275 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,679,282 | 3 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,317,703 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Proposal 2: The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”): 64,712,039 for, 174,706 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 82% for, 0.3% against (83% of the company cast a for/against vote).
The 65 asset managers below cast 99.9% of the shares they voted on this item FOR (26,359,544 for, 39 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,679,285 | 0 | 0 | 0 | For |
| Fidelity | 4,430,076 | 0 | 0 | 0 | For |
| BlackRock | 2,612,329 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,923,039 | 0 | 0 | 0 | For |
| State Street | 1,317,664 | 39 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 1,049,614 | 0 | 0 | 0 | For |
| American Century | 683,198 | 0 | 0 | 0 | For |
| Charles Schwab | 630,314 | 0 | 0 | 0 | For |
| TIAA | 554,035 | 0 | 0 | 0 | For |
| Hartford | 522,084 | 0 | 0 | 0 | For |
| Dimensional | 296,337 | 0 | 0 | 0 | For |
| Goldman Sachs | 271,708 | 0 | 0 | 0 | For |
| Federated Hermes | 258,827 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 197,835 | 0 | 0 | 0 | For |
| Equitable | 159,151 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,685 | 0 | 0 | 0 | For |
| First Trust | 127,006 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 124,132 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 111,474 | 0 | 0 | 0 | For |
| DWS | 96,496 | 0 | 0 | 0 | For |
| John Hancock | 91,334 | 0 | 0 | 0 | For |
| JPMorgan | 83,467 | 0 | 0 | 0 | For |
| Brighthouse | 76,162 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 63,850 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,385 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
98% Majority: yes · of votes cast
Celldex Therapeutics, Inc.’s own tally for this item (“Proposal 4: The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement.”): 59,258,619 for, 945,414 against, per its Form 8-K filed 2026-06-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,492,072 outstanding shares: 75% for, 1% against (77% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (25 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 25 | 0 | 0 | 0 | For |
| Ikarian Capital, LLC | 0 | 0 | 0 | 0 | -- |
Ranked by the number of Celldex Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 78,492,072 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 13.09% |
| 2 | Wellington | 10.89% |
| 3 | Fidelity | 10.43% |
| 4 | Kynam Capital Management, LP | 7.30% |
| 5 | BlackRock | 6.94% |
| 6 | T. Rowe Price | 6.08% |
| 7 | State Street | 3.60% |
| 8 | Commodore Capital LP | 2.68% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.45% |
| 10 | Eversept Partners, LP | 1.98% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Wellington Management | 10.91% | 13F |
| Kynam Capital Management, LP | 8.28% | DEF14A |
| BlackRock | 6.84% | 13F |
| FMR LLC | 6.19% | DEF14A |
| Vanguard Group | 5.13% | 13F |
| FMR (Fidelity) | 4.78% | 13F |
| Point72 | 4.11% | 13F |
| State Street | 3.57% | 13F |
| T. Rowe Price | 2.66% | 13F |
| Millennium Management | 1.60% | 13F |
Percentages above are of 78,492,072 shares outstanding, as reported by Celldex Therapeutics, Inc. on its Form 10-Q dated 2026-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Celldex Therapeutics, Inc.’s 10-Q dated 2026-04-29. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Celldex Therapeutics, Inc.'s shareholder meeting held 2026-06-25, in the 2025-2026 proxy season, 256 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,066 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Celldex Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-26.
Celldex Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).